deltatrials
Completed PHASE1/PHASE2 NCT01004770

Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)

An Intravenous, Single Dose Safety, Tolerance and Pharmacokinetic Study of GE-145 in Healthy Volunteers Undergoing a Contrast-enhanced Abdominal Computed Tomography (CT) Scan

Sponsor: GE Healthcare

Conditions Healthy
Interventions GE-145 (AN113111) Injection Visipaque (iodixanol) Injection
Updated 8 times since 2017 Last updated: Apr 4, 2012 Started: Oct 31, 2009 Primary completion: Feb 28, 2010 Completion: May 31, 2010

A PHASE1/PHASE2 clinical study on Healthy, this trial is completed. The trial is conducted by GE Healthcare and has accumulated 8 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GE Healthcare
  • Medpace, Inc.
  • i3 Statprobe
Data source: GE Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Princeton, United States